AzTrials
AzTrials

Rheumatoid ArthritisPhase 2DARWIN3NCT02065700

Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants

A Phase 2 study testing Filgotinib in people with Rheumatoid Arthritis, run by Lakefront Biotherapeutics NV at 111 sites in 22 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The primary objective of the study was to evaluate the long-term safety and tolerability of filgotinib (formerly GLPG0634) for the treatment of rheumatoid arthritis. Participants were enrolled in this open-label long-term follow-up study after they had completed one of the two core studies, GLPG0634-CL-203 (DARWIN1)… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
Filgotinib
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
739 participants
Where
111 sitesin 22 countries
Study dates
25 Feb 2014to 19 Jan 2023
Phase
Phase 2

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Participants who completed one of the qualifying core studies GLPG0634-CL-203 or GLPG0634-CL-204 and may benefit from filgotinib long-term treatment according to the Investigator's judgment
  • Females of childbearing potential and sexually active men must agree to use highly effective method of birth control as specified in the protocol, during the study and for at least 12 weeks after the last dose of filgotinib

Who cannot join

  • Participants who prematurely withdrew from one of the 2 core studies (GLPG0634-CL-203 or GLPG0634-CL-204), for any reason
  • Persistent abnormal lab values during one of the 2 core studies (GLPG0634-CL-203 or GLPG0634-CL-204), according to the Investigator's judgment
  • Diagnosis of rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid arthritis, except for secondary Sjogren's syndrome
  • Any condition or circumstances which, in the opinion of the Investigator, may make a participant unlikely or unable to complete the study or comply with study procedures and requirements
  • Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Trial locations and contacts

111 sites in 22 countries.

111 sites in 22 countries

United States15 sites
  • Austin Rheumatology Research PA

    Austin, Texas

  • RASF Clinical Research Center

    Boca Raton, Florida

  • Low County Rheumatology PA

    Charleston, South Carolina

  • Arthro, Arthritis Care & Research

    Gilbert, Arizona

  • Physicians East

    Greenville, North Carolina

  • Klein and Associates MD, PA

    Hagerstown, Maryland

  • C.V. Mehta MD Medical Corp.

    Hemet, California

  • Pioneer Research Solutions Inc

    Houston, Texas

  • West Tennessee Research Institute

    Jackson, Tennessee

  • Arizona Arthritis & Rheumatology Research PLLC

    Mesa, Arizona

  • Health Research of Oklahoma

    Oklahoma City, Oklahoma

  • Millenium Research

    Ormond Beach, Florida

  • Desert Medical Advances

    Palm Desert, California

  • Springfield Clinic

    Springfield, Illinois

  • Lovelace Scientific Resources

    Venice, Florida

Other trials in United States

Poland11 sites
  • NZOZ Osteo-Medic s.c.

    Bialystok

  • Centrum Medyczne Silesiana Sp. Z.o.o.

    Bytom

  • Centrum Medyczne Pratia Katowice

    Katowice

  • Centrum Medyczne Plejady

    Krakow

  • NZOZ "DOBRY LEKARZ" Specjalistyczne Poradnie Lekarskie

    Krakow

  • Specjalistyczne Centrum Medyczne Nowomed

    Krakow

  • NZOZ Przychodnia Lekarska "Eskulap"

    Skierniewice

  • Powiatowy Zaklad Opieki Zdrowotnej w Starachowicach

    Starachowice

  • NZOZ "Nasz Lekarz" Pratyka Grupowa Lekarzy Rodzinnychz

    Torun

  • AMED Medical Center

    Warsaw

  • Rheumatica Sp. Z.o.o.

    Warsaw

Other trials in Poland

Argentina8 sites
  • Atencion Integral en Reumatologa

    Buenos Aires

  • CER Intituto Medico

    Buenos Aires

  • Organizacion Medica de Investigaciones (OMI)

    Buenos Aires

  • Instituto Reumatologico Strusberg

    Córdoba

  • CIMeL Centro dee Investigacion Medico Lanus

    Lanus

  • Instituto CAICI

    Rosario

  • Instituto de Asistencia Reumatologia Integral - IARI

    San Fernando

  • Centro Médico Privado de Reumatologia

    San Miguel de Tucumán

Other trials in Argentina

Russia8 sites
  • First Moscow State Medical University n.a. I.M. Sechenova of the Ministry of Health

    Moscow

  • Scientific Research Institute of Rheumatology

    Moscow

  • City Clinical Hospital #5

    Nizhny Novgorod

  • GBOU VPO Orenburg State Medical University

    Orenburg

  • Ryazan State Medical University

    Ryazan

  • City Hospital #26

    Saint Petersburg

  • Regional Clinical Hospital

    Saratov

  • Vladimir Regional State Instituion of Healthcare

    Vladimir

Other trials in Russia

Colombia7 sites
  • Circaribe S.A.S

    Barranquilla

  • Centro de Investigacion en Reumatologia y Especialidades Medicas (CIREEM)

    Bogotá, 110221

  • Riesgo De Fractura Cayre Ips7

    Bogotá, 110221

  • Idearg Sas

    Bogotá

  • Medicity S.A.S.

    Bucaramanga, Santander Department

  • Preventive Care SAS

    Cundinamarca

  • Hospital Pablo Tobon Uribe

    Medellín

Other trials in Colombia

Mexico7 sites
  • Centro de Estudios de Investigacion Basica y Clinica, SC

    Guadalajara

  • Arke Estudios Clinicos S.A. de C.V.

    México

  • Clinstile, S.A. de C.V.

    México

  • Hospital General de México

    México

  • Centro Medico Dalinde

    Mexico City

  • Hospital Universitario José E. Gonzalez

    Monterrey

  • OSMO

    Oaxaca City

Other trials in Mexico

Ukraine7 sites
  • Communal Institution of Healthcare - Kharkiv City Clinical Hospital #13

    Kharkiv

  • Kharkiv Medical Academy of Postgraduate Education, Department of Cardiology

    Kharkiv

  • L.T. Malaya Therapy Institute of National Academy of Medical Sciences of Ukraine

    Kharkiv

  • Kherson City Clinical Hospital N. A. Afanasii and Olga Tropin

    Kherson

  • Municipal Non-Profit Institution Consultative and Diagnostic Centre of Desnyasky District of Kyiv

    Kiev

  • Municipal Non-profit Enterprise Consultative and Diagnostic Center of Pechersk District of Kiev city

    Kyiv

  • Vinnitsya Regional Clinical Hospital Named after M.I.Pirogov, Rheumatology Department

    Vinnytsia

Other trials in Ukraine

Guatemala6 sites
  • Centro Clinico

    Guatemala City

  • Clinica de Especialidades Medicas

    Guatemala City

  • Clinica Medica Especializada en Reumatologia

    Guatemala City

  • Clinica Medica

    Guatemala City

  • Reuma S.A.

    Guatemala City

  • Reuma-Centro

    Guatemala City

Other trials in Guatemala

Bulgaria5 sites
  • University "Multiprofile Hospital for Active Treatment - Kaspela" LTD

    Plovdiv

  • Multiprofile Hospital for Active Treatment - Ruse

    Rousse

  • Diagnostic Consultative Center "Sveta Anna" LTD

    Sofia

  • National Multiprofile Transport Hospital "Tsar Boris III," Sofia, Clinical of Internal Diseases

    Sofia

  • University Multiprofile Hospital for Active Treatment "SV. Ivan Rilski" EAD, Sofia, Rheumatology Clinic

    Sofia

Other trials in Bulgaria

Chile5 sites
  • Hospital Regional "Guillermo Grant Benavente"

    Santiago

  • Prosalud

    Santiago

  • Someal SA

    Santiago

  • Centro de Investigacion Clinica del Sur

    Temuco

  • Consulta Privada Dra. Ponce

    Temuco

Other trials in Chile

Hungary5 sites
  • Gyogyszervizs galo Kozpont Kft

    Balatonfüred

  • QualiClinic Kft.

    Budapest

  • Reumatologiai Kft.

    Budapest

  • Markhot Ferenc Hospital, Rheumatology

    Eger

  • Csolnoky Ferenc Hospital, Rheumatology

    Veszprém

Other trials in Hungary

Latvia5 sites
  • Ltd M&M Centr

    Adazi

  • SIA Arijas Ancane's Family Doctor

    Baldone

  • Daugavpils Regional Hospital

    Daugavpils

  • L. Atikes doktorats

    Liepāja

  • 'Bruninieku' polyclinic

    Riga

Other trials in Latvia

Czechia4 sites
  • Revmatologie S.R.O

    Brno

  • Revmatologicka a interni ambulance

    Kladno

  • Revmatologicka ambulance

    Praha-Nusle

  • PV-Medical S.R.O.

    Zlín

Other trials in Czechia

Australia3 sites
  • Flinders Medical Centre

    Bedford Park, Flinders Drive, South Australia

  • Monash Medical Centre

    Clayton, Victoria

  • Princess Alexandra Hospital

    Woolloongabba

Other trials in Australia

Spain3 sites
  • Complejo Hospitalario Universitario A Coruña (CHUAC)

    A Coruña

  • Sanatorio Nuestra Señora de la Esperanza

    A Coruña

  • Hospital Parc Tauli

    Sabadell

Other trials in Spain

Belgium2 sites
  • Cliniques Universitaires St-Luc

    Brussels

  • UZ Leuven

    Leuven

Other trials in Belgium

Germany2 sites
  • Schlossparkklinik - Akad. Lehrkrankenhaus Charite

    Berlin

  • MVZ Rheumatologie and Autoimmun Medizin HH GmbH

    Hamburg

Other trials in Germany

Israel2 sites
  • Carmel Medical Center

    Haifa

  • Rambam Medical Center

    Haifa

Other trials in Israel

New Zealand2 sites
  • Waikato Hospital

    Hamilton

  • Timaru Rheumatology Studies

    Timaru

Other trials in New Zealand

Romania2 sites
  • Spitalul Clinic Sfanta Maria

    Bucharest

  • Spitalul Clinic Judetean de Urgenta Sf. Apostol Andrei Galati

    Galati

Other trials in Romania

France1 site
  • Hospitaux de Hautepierre

    Strasbourg

Other trials in France

Moldova1 site
  • IMSP Institutul de Cardiologie

    Chisinau

Other trials in Moldova

About this study

Official title: A Multicenter, Open-label, Long-term Follow-up Safety and Efficacy Study of GLPG0634 Treatment in Subjects With Moderately to Severely Active Rheumatoid Arthritis

The primary objective of the study was to evaluate the long-term safety and tolerability of filgotinib (formerly GLPG0634) for the treatment of rheumatoid arthritis.

Participants were enrolled in this open-label long-term follow-up study after they had completed one of the two core studies, GLPG0634-CL-203 (DARWIN1) (NCT01888874) or GLPG0634-CL-204 (DARWIN2) (NCT01894516), and were evaluated for any side effects that might have occured (long-term safety and tolerability) when taking filgotinib. During the course of the study, participants were also examined for long-term effects of filgotinib administration on disease activity (efficacy), participant's disability, fatigue, and quality of life.

Being tested
Filgotinib
Keywords
Methotrexate, insufficient responders
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • FilgotinibDrug

    Also called GS-6034, GLPG0634

    Administered as Oral Tablets

Study groups in NCT02065700
Study groupRoleWhat they receive
Filgotinib Darwin 1ExperimentalParticipants in Study GLPG0634-CL-203 (NCT01888874) were rolled-over to receive an oral dose of filgotinib at a daily dose of 200 milligrams (mg) in this extension study, with the exception of male participants in the United States (US) who were limited to a daily dose of 100 mg due to a Food and Drug Administration (FDA) requirement based on a non-clinical finding. Treatment was administered until marketing, local (if applicable) regulatory and/or pertinent local reimbursement approval. In case of intolerance or for safety reasons, and as per investigator's discretion, a daily dose of filgotinib 200 mg could be decreased to 100 mg per day, and later returned to 200 mg per day after the reasons for decreasing the dose were resolved.
Receives: Drug: Filgotinib
Filgotinib Darwin 2ExperimentalParticipants from Study GLPG0634-CL-204 (NCT01894516) were rolled-over to receive oral dose of filgotinib tablet at 200 mg once daily (q.d) in this extension study. Treatment was administered until marketing, local (if applicable) regulatory and/or pertinent local reimbursement approval. Participants started the study with the same dose level (filgotinib 200 mg per day) and in case of intolerance or safety reasons and as per investigator's discretion, the daily dose of filgotinib was decreased to 100 mg q.d and was returned to 200 mg per day after the reasons for decreasing the dose had resolved and at the investigator's discretion.
Receives: Drug: Filgotinib

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants Experiencing Treatment-Emergent Adverse Events

    An Adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.

    Treatment-emergent adverse events (TEAEs) were defined as any AEs with an onset date on or after the filgotinib start date in the core studies or GLPG0634-CL-205 (NCT02065700), and no later than 30 days after permanent discontinuation of filgotinib in GLPG0634-CL-205 (NCT02065700) or of either 30 days after the last dose date.

    Measured: From First dose to Week 437

Secondary outcomes (16)
  1. Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Response: Non-Responder Imputation (NRI)

    The American College of Rheumatology (ACR) response was a measurement of improvement in multiple disease assessment criteria.

    The ACR20 response was defined as: 1) ≥ 20% improvement from baseline in swollen joint count 66 (SJC66), and 2) ≥ 20% improvement from baseline in tender joint count 68 (TJC68), and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain visual analog scale (VAS) (taken from the Health Assessment Questionnaire - Disability Index [HAQ-DI]), 2.Subject's Global Assessment of Disease Activity (SGA) (VAS), 3. Physician's Global Assessment of Disease Activity (PGA) (VAS), 4. Total HAQ-DI score, and 5. High-Sensitivity C- Reactive Protein (hsCRP).

    Measured: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  2. Percentage of Participants Achieving ACR20 Response: Observed Case (OC)

    The ACR response was a measurement of improvement in multiple disease assessment criteria.

    The ACR20 response was defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in tender TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5. hsCRP.

    Measured: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  3. Percentage of Participants Achieving ACR50 Response: NRI

    The ACR response was a measurement of improvement in multiple disease assessment criteria.

    ACR50 response was defined as: 1) ≥ 50% improvement from baseline in SJC66, and 2) ≥ 50% improvement from baseline in TJC68, and 3) ≥ 50% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI) 2.SGA (VAS) 3. PGA (VAS) 4. Total HAQ-DI score 5. hsCRP.

    Measured: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  4. Percentage of Participants Achieving ACR50 Response: OC

    The ACR response was a measurement of improvement in multiple disease assessment criteria.

    ACR50 response was defined as: 1) ≥ 50% improvement from baseline in SJC66, and 2) ≥ 50% improvement from baseline in TJC68, and 3) ≥ 50% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI) 2.SGA (VAS) 3. PGA (VAS) 4. Total HAQ-DI score 5. hsCRP.

    Measured: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  5. Percentage of Participants Achieving ACR70 Response: NRI

    The ACR response was a measurement of improvement in multiple disease assessment criteria.

    ACR70 response was defined as : 1) ≥ 70% improvement from baseline in SJC66, and 2) ≥ 70% improvement from baseline in TJC68, and 3) ≥ 70% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5. hsCRP.

    Measured: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  6. Percentage of Participants Achieving ACR70 Response: OC

    The ACR response was a measurement of improvement in multiple disease assessment criteria.

    ACR70 response was defined as : 1) ≥ 70% improvement from baseline in SJC66, and 2) ≥ 70% improvement from baseline in TJC68, and 3) ≥ 70% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5.hsCRP.

    Measured: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  7. ACR N% Improvement (ACR-N) Response: OC

    ACR-N was defined as the smallest percentage improvement from core baseline in SJC66, TJC68 and the median of the following 5 items (Pain VAS [taken from the HAQ-DI], 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5. hsCRP). It had a range between 0 and 100%.

    Measured: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  8. Change From Core Baseline in Disease Activity Score Based on 28 Joints Using C-reactive Protein (DAS28[CRP]): OC

    The DAS28(CRP) was a measure of the participant's disease activity calculated using the TJC (28 joints), SJC (28 joints), SGA [using a VAS on a scale of 0 (very well) to 100 (very poor)] and hsCRP using the formula:

    DAS28(CRP) = 0.56 * Square root [SQRT] (TJC28) + 0.28 * SQRT(SJC28) + 0.36 * Ln(CRP+1) + 0.014 * SGA + 0.96

    and the total possible score ranged from 1 to 9.4. Higher values indicated higher disease activity. A negative change from baseline indicated improvement.

    Measured: Core Baseline, Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  9. Change From Core Baseline in Simple Disease Activity Index (SDAI): OC

    SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA (0 to 10 cm), PGA (0 to 10 cm), CRP (mg/dL). SDAI = TJC + SJC + SGA + PGA+ CRP. The SDAI score ranged from 0 to approximately 86. Higher SDAI indicated greater disease activity. A negative change from baseline indicated improvement.

    Measured: Core Baseline, Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  10. Change From Core Baseline in Clinical Disease Activity Index (CDAI): OC

    The CDAI was the SDAI modified that excluded CRP and consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA (0 to 10 cm), PGA (0 to 10 cm). SDAI = TJC + SJC + SGA+ PGA. The CDAI score ranged from 0 to approximately 76. Higher CDAI indicated greater disease activity. A negative change from baseline indicated improvement.

    Measured: Core Baseline, Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  11. Percentage of Participants Achieving European League Against Rheumatism (EULAR) Response: OC

    DAS28(CRP) was categorized into EULAR response categories (none, moderate, good) as follows:

    None= Actual DAS28(CRP) ≤ 3.2, > 3.2 to ≤ 5.1, or > 5.1 AND Improvement in DAS28(CRP) from baseline ≤ 6.0 or > 0.6 to ≤ 1.2;

    Moderate= Actual DAS28(CRP) ≤ 3.2 AND Improvement in DAS28(CRP) from baseline > 0.6 to ≤ 1.2, Actual DAS28(CRP) > 3.2 to ≤ 5.1 or > 5.1 AND Improvement in DAS28(CRP) from baseline > 1.2, or Actual DAS28(CRP) > 3.2 to ≤ 5.1 AND Improvement in DAS28(CRP) from baseline > 0.6 to ≤ 1.2;

    Good= Actual DAS28(CRP) ≤ 3.2 AND Improvement in DAS28(CRP) from baseline > 1.2.

    Measured: Core Baseline, Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  12. Percentage of Participants Achieving ACR/EULAR Remission: NRI

    A participant's disease activity status was defined as being in remission when scores on the TJC28, SJC28, CRP (actual value in mg/dL) and SGA (cm) were all ≤ 1.

    Measured: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  13. Percentage of Participants Achieving ACR/EULAR Remission: OC

    A participant's disease activity status was defined as being in remission when scores on the TJC28, SJC28, CRP (actual value in mg/dL) and SGA (cm) were all ≤ 1.

    Measured: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  14. Change From Core Baseline in Physical Component Score (PCS) of Quality of Life Using the Short Form-36 (SF-36) Scores: OC

    The health-related quality of life of the subject was assessed using the SF-36 with a 4-week recall period. This consists of 36 questions belonging to 8 domains in 2 components:

    • Physical well-being: 4 domains: physical functioning (10 items), role physical (4 items), bodily pain (2 items), and general health (GH) perceptions (5 items).
    • Mental well-being: 4 domains: vitality (4 items), social functioning (2 items), role emotional (3 items), and mental health (5 items).

    These scales were from 0 to 100 with higher scores indicating a better quality of life.

    Measured: Core Baseline, Extension Baseline, Weeks 48, 96, 144, 192, 240, 288, 336, 384

  15. Change From Core Baseline in MCS of Quality of Life Using the SF-36 Scores: OC

    The health-related quality of life of the subject was assessed using the SF-36 with a 4-week recall period. This consists of 36 questions belonging to 8 domains in 2 components:

    • Physical well-being: 4 domains: physical functioning (10 items), role physical (4 items), bodily pain (2 items), and general health (GH) perceptions (5 items).
    • Mental well-being: 4 domains: vitality (4 items), social functioning (2 items), role emotional (3 items), and mental health (5 items).

    These scales were from 0 to 100 with higher scores indicating a better quality of life.

    Measured: Core Baseline, Extension Baseline, Weeks 48, 96, 144, 192, 240, 288, 336, 384

  16. Change From Core Baseline in Quality of Life Using Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale: OC

    FACIT-Fatigue scale was a 13-item questionnaire, each scored on a 5-point scale: 0 (Not at all) to 4 (Very much). Negatively stated items were reversed by subtracting the response from "4" before being added to obtain a total score. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score), with a higher score indicating less fatigue. A positive change from baseline indicated better quality of life.

    Measured: Core Baseline, Extension Baseline, Weeks 48, 96, 144, 192, 240, 288, 336, 384

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Feb 2014 (estimated)
  2. Study start25 Feb 2014
  3. Primary completion19 Jan 2023
  4. Study completion19 Jan 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
739 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02065700
Sponsor's protocol ID
GLPG0634-CL-205
Other IDs
2012-003655-11
Acronym
DARWIN3
Status last verified
May 2024
First submitted
14 Feb 2014
Last updated
4 Jun 2024
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Qualified external researchers may request IPD for clinical trials that support an approved indication in the EU and the US for which Galapagos is the Marketing Authorisation / New Drug Application Holder, with a marketing authorisation date on or after January 1, 2021 and for which the summary results have been published on ClinicalTrials.gov (CT.gov) and/or the EU Clinical Trials Register (EU CTR). For clinical trials of newly approved compounds or indications the IPD can be requested at earliest 6 months after the EMA and FDA approval. The study last patient last visit (LPLV) must have occurred at least 18 months prior to the request.

Publications

  • Genovese MC, Kavanaugh A, Winthrop K, et al. Long Term Safety of Filgotinib in the Treatment of Rheumatoid Arthritis: Week 84 Data from a Phase 2b Open-Label Extension Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10).

  • Kavanaugh A, Westhovens R, Winthrop K, et al. Rheumatoid Arthritis Treatment with Filgotinib: Week 156 Safety and Efficacy Data from a Phase 2b Open-Label Extension Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).

  • R. Westhovens, R. Alten, K. Winthrop, et al. Long term safety of filgotinib in the treatment of rheumatoid arthritis: week 108 data from a phase 2b open-label extension study. [abstract]. Ann Rheum Dis. 2018;77 (suppl 2)

  • Kavanaugh A, Genovese MC, Winthrop K, et al. Rheumatoid Arthritis Treatment with Filgotinib: Week 132 Safety Data from a Phase 2b Open-Label Extension Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9).

  • Kavanaugh A, Westhovens RR, Winthrop KL, Lee SJ, Tan Y, An D, Ye L, Sundy JS, Besuyen R, Meuleners L, Stanislavchuk M, Spindler AJ, Greenwald M, Alten R, Genovese MC. Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs. J Rheumatol. 2021 Aug;48(8):1230-1238. doi: 10.3899/jrheum.201183. Epub 2021 Feb 1.

    PubMed 33526618
  • Westhovens R, Winthrop KL, Kavanaugh A, Greenwald M, Dagna L, Cseuz R, Besuyen R, de Vries D, Modgill V, Le LH, Genovese MC, Emery P, Verschueren P, Alten R. Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study. RMD Open. 2025 Jan 30;11(1):e004857. doi: 10.1136/rmdopen-2024-004857.

    PubMed 39884731
  • Balsa A, Wassenberg S, Tanaka Y, Tournadre A, Orzechowski HD, Rajendran V, Lendl U, Stiers PJ, Watson C, Caporali R, Galloway J, Verschueren P. Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis. Rheumatol Ther. 2023 Dec;10(6):1555-1574. doi: 10.1007/s40744-023-00599-1. Epub 2023 Sep 25.

    PubMed 37747626
  • Combe B, Besuyen R, Gomez-Centeno A, Matsubara T, Sancho Jimenez JJ, Yin Z, Buch MH. Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis. Rheumatol Ther. 2023 Feb;10(1):35-51. doi: 10.1007/s40744-022-00494-1. Epub 2022 Oct 7.

    PubMed 36205910

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in